‘Practice changing’ results presented at the American Society for Bone and Mineral Research (ASBMR) in Montreal confirm the value of extending bisphosphonate treatment to postmenopausal women with osteopenia. The findings, published concurrently in the New England Journal of Medicine, will influence future clinical guidelines and challenge PBS rules regarding the drug’s reimbursement, according to endocrinologist ...
Zoledronate results support bisphosphonate use in osteopenia
By Mardi Chapman
2 Oct 2018